by Paul FassaHealth Impact News
Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S.
There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patients own stem cells, so no patent-able drugs are involved.
They are targetingthe most influential stem cell scientist in the U.S., Dr.Kristin Comella in Florida.
Many consider stem cell therapy the future of medicine. A stem cell can rebuild or create new cells in tissues, even in organ tissues other than those from which they had originally existed.
They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.
There is a considerable controversy surrounding stem cell therapy research, a branch ofregenerative medicine. Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.
Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.
Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patients own adipose tissue and inject them into areas where that same patient needs repair. Its an autologous process called adult stem cell therapy.
U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinics Chief Scientist isDr. Kristin Comella, PhD.
Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.
Dr. Kristin Comellaand her clinichave been under attack from theFDA.
This short 3-minute video was produced interviewing Dr. Comella and some of her patients.
Human embryonic stem cell (hESC) therapy has received most of the medias attention and government support. But it is the most controversial because it involves extracting tissues from terminated human embryos, aka aborted fetuses.
In addition to moral and ethical issues, human embryonic stem cell (hESC) solutions create cells so rapidly where theyre injected they lead to cancerous tumors. To avoid that, researchers have to use immuno-suppressant drugs to curb the embryonic stem cells tendency toward cancer.
Using pharmaceutical drugs to curb hESC cancer side effect issues leads to other unexplored and unexpected side effects from those patented stem cell solutions.
But the profit motive for embryonic stem cell therapies was strong and a lot of government funds had been put into its research. Pharmaceutical companies were motivated because they could patent stem cells created from embryonic tissues.
Bone marrow stem cell therapy was among the first to depart from flawed hESC (human embryonic stem cell) therapies developed over the past two decades.Bone marrow stem cell therapy was the segue into the adult stem cell therapy movement.
Bone marrow extractions are painful, requiring general anesthesia. Its relatively difficult and expensive compared to adipose (fat) tissue stem cell harvesting.
Bone marrows high white blood cell count also encourages inflammation, making it counter-productive for patients already suffering from chronic inflammation or autoimmune disorders.
Most importantly, adipose (fat) tissue yields up to 500 times more mesenchymal stem cells than bone marrow sources, according to Dr. Comella. These are potent stem cells that can differentiate into a wide variety of other cell types. Furthermore, the adipose white blood cell count is lower than bone marrow matter.
Overactive, confused immune responses attack organs continually and create chronic inflammation and autoimmune diseases. The lower white blood cell count automatically lowers the risk of further inflammation among patients already suffering from chronic inflammation and autoimmune diseases.
The outpatient treatment involves creating a very small and shallow incision that wont require stitches on an area of skin covering adipose tissue (fat). From there, liposuction can withdraw a portion of the fat. This part of the procedure requires only a local anesthetic.
Then what is extracted is spun at high speed in a special centrifuge to isolate the stem cells which are then purified for IV drip delivery or injection into the same patient from whom it was extracted. Total costs range from five to ten thousand dollars or more in some cases.
Dr. Comella and her colleagues mission is to get adult stem cell therapy available for everyone. Private and government health insurance providers cover medical treatments that are much more expensive.
Why not cover one that would save money with its lower expense and fewer side effects?
Over the years, there have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions as well as heart and lung issues.
But the three known adverse side effect cases continually get all the media attention.
The Panama College of Cell Science, which helped launch Kristin Comellas research and development, had this to say about her:
Perhaps the most influential clinician on the subject of adult stem cell therapy, Dr. Comella has been able to quietly develop patient treatment protocols and treat patients via collaborating physicians and health care providers using legal patient-specific FDA guidelines, including studies permitted by Institutional Review Boards, patient-specific stem cell clinical trials, and direct treatments using the patients own stem cells that are harvested and re-injected for therapeutic purposes.
Through Dr. Comellas leadership, she and her team have trained and certifiedmore than 700 physicians worldwide in adult stem cell therapy. (Source)
The interview below allows the energetic Dr. Kristin Comella to give a thorough and upbeat description of adult stem cell therapy.
Since the late 1990s, adult stem cells used therapeutically were not under the control of the FDA and the adult stem cell movement took off.
There were complaints from some MDs that the adult stem cell practice should be regulated by the FDA. The Panama College of Cell Science responded to those outcries with this statement:
The motive in opposing adult stem cell therapy is money. The big institutions want to keep federal funding of embryonic stem cell research at a high level with the promise that cures are just around the corner despite the fact that embryonic stem cells will never be useful in any way for patient treatment because they immediately cause tumors when transplanted. (Source)
Adult stem cell therapy is an autologous treatment method. The stem cells are not lab-created. They are only isolated and purified after extracting them from the patient being treated. Injecting them back into that patient powers up the bodys own healing mechanism to overcome chronic ailments.
The FDA didnt and shouldnt have anything to do with regulating stem cells from ones own body. That situation has recently been arbitrarily and suddenly changed.
Around 2014, the FDA started tweaking their guidance rules for stem cell therapy with the purpose of getting new rules made into laws through Congress that could be interpreted according to FDA whims and enforced arbitrarily. Their agenda is to consider adult stem cells as FDA-regulated drugs.
During our phone conversation, Dr. Comella explained how the FDA ignored testimonies from adult stem cell practitioners during their 2015 public hearings regarding new guideline proposals. Then they arranged to create new rules behind closed door meetings that included pharmaceutical industry allies and insiders.
The result was that by 2017, the FDAs hands-off policy with adult stem cell therapy came to a sudden halt after years of highly successful stem cell practice.
By 2018, the FDA got nastier with the the most influential clinician on the subject of adult stem cell therapy as its target. The FDA started doing inspections of Dr. Comellas South Florida clinic that aredesigned for labs that manufacture drugs.
The standards for hospitals and clinics are not as strict as drug manufacturers. Those inspections were inappropriate for a clinic. But those inspectionsmade it easier to create damaging reports.
When the inspectors came by, they demanded to go into rooms while treatments were taking place with semi-nude or nude patients, which Dr. Comella prohibited. The inspectors also demanded to view patient medical records. She allowed that after redacting their names on the copies she gave them.
For her actions to protect patients privacy, inspectors allegedly cited Dr. Comella for resisting and obstructing FDA inspections.
Soon after the inspections, the FDA served Dr. Comella with a lawsuit for practicing medicine with unapproved drugs. The drugs were only those stem cell solutions drawn from patients to be used on them.
The FDA has allegedly offered to drop the lawsuit if Dr. Comella signed an agreement to stop doing adult stem cell therapy and no longer promote it.
She refused. She said she has witnessed people leave their wheelchairs for good from this therapy. The trial is set for a Federal Court hearing beginning June 2019, in Miami, Florida.
If Dr. Comella loses this court case, adult stem cell therapy in the USA may be forced out of the country and only be available to those who can affordmedical tourism.
Published on March 11, 2019
See more here:
FDA Wants to Shut Down Adult Stem Cell Therapy as its Healing ...
- Revolutionizing medicine: recent developments and future prospects in ... - December 28th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 28th, 2024
- The therapeutic potential of stem cells - PMC - December 19th, 2024
- Researchers find success with stem cell therapy in mice model of ... - December 19th, 2024
- Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene ... - December 19th, 2024
- Study finds stem cell therapy is safe and may benefit people with ... - October 22nd, 2024
- Stem Cell Therapy Market Size to Hit USD 48.89 Billion by 2033 - GlobeNewswire - October 22nd, 2024
- Eves dream to walk: Family raising vital funds for two-year-olds stem cell therapy - Her.ie - October 22nd, 2024
- Stem cell therapies for chronic obstructive pulmonary disease ... - September 21st, 2024
- Magellan Stem Cells welcomes $7 million federal government grant - September 21st, 2024
- Stem Cell Therapy Research: Creative Biolabs Advances iPSC-Derived Macrophage Solutions - openPR - September 21st, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 21st, 2024
- Stem cells: Therapy, controversy, and research - Medical News Today - September 4th, 2024
- Stem cell-based therapy for human diseases - PMC - September 4th, 2024
- Bone marrow mesenchymal stem cells in treatment of peripheral nerve ... - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 5th, 2024
- Putting Stem Cell-Based Therapies in Context | National Institutes of ... - April 8th, 2024
- Eggs from men, sperm from women: Stem cell therapy may just turn reproduction upside down! - The Economic Times - January 17th, 2024
- Stem Cell Therapy: From Idea to Clinical Practice - PMC - December 13th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 18th, 2023
- Stem Cell Therapy Is It Right for You? Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy | Mellon Center Approach | Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - December 3rd, 2022
- Canine Stem Cell Therapy Market Size 2022 with a CAGR of % Market Share, prime companies report covers, world business Trends, Statistics, Definition,... - June 16th, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 16th, 2022
- Sutton boy pledges to raise money to help his brother with autism go to America for stem cell therapy - Mansfield and Ashfield Chad - June 16th, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 16th, 2022
- Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01 - Yahoo Finance - June 16th, 2022
- Stem cell therapy shows promise in aiding equine wound healing - Horsetalk.co.nz - Horsetalk - April 2nd, 2022
- Rheumatoid Arthritis Stem Cell Therapy Market Assessment, With Major Top Companies Analysis, Geographic Analysis, Growing Opportunities Data By... - April 2nd, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 2nd, 2022
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 7th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 4th, 2021
- Multiple myeloma stem cell transplant: What happens and more? - Medical News Today - August 4th, 2021
- Animal Stem Cell Therapy Market Research 2021-2027 With Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, US Stem Cell The Manomet Current - The... - August 4th, 2021
- Global Stem Cell Therapy Market to witness exponential proliferation during 2020-2026 The Manomet Current - The Manomet Current - August 4th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 26 Sports - 2x6 Sports - July 21st, 2021
- NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire - June 24th, 2021
- Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,... - June 24th, 2021
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene... - June 24th, 2021
- Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire - June 24th, 2021
- Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert - March 3rd, 2021
- Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian - March 3rd, 2021
- Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering - March 3rd, 2021
- NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com - March 3rd, 2021
- Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News - March 3rd, 2021
- We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT - March 3rd, 2021
- Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -... - March 3rd, 2021
- Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU... - March 3rd, 2021
- Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The... - March 3rd, 2021
- Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv... - March 3rd, 2021
- Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance - Magazine of Santa Clarita - March 3rd, 2021
- Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY... - March 3rd, 2021
- Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The... - March 3rd, 2021
- Exclusive Insights on Stem Cell Therapy for Multiple Sclerosis Market 2021-2026: Latest Trends, Drivers, Strategies and Competitive Landscape The... - March 3rd, 2021
- Stem Cell Therapy Market By Treatment,Application,End Users And Geography Forecast To 2027 The Bisouv Network - The Bisouv Network - March 3rd, 2021
- 10 Best Clinics for Stem Cell Therapy in Thailand [2021 ... - February 14th, 2021
- Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung... - February 14th, 2021
- Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning... - February 14th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 14th, 2021
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2025 FLA... - February 14th, 2021
- Dancing on Ice's Colin Jackson to get stem cell op as he's got 'knees of 85-year-old' - Mirror Online - February 1st, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 31st, 2021
- ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web - January 31st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 31st, 2021
- ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -... - January 31st, 2021
- Stem Cell Therapy for Diabetes and Related Conditions Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2025 - AlgosOnline - January 31st, 2021
- Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ - January 31st, 2021
- Animal Stem Cell Therapy Market to witness high growth in near future - Fractovia News - January 31st, 2021
- Regenerative medicine is advancing health care in diverse ways - Hometown Focus - January 23rd, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace - January 23rd, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 23rd, 2021